#biotech IPO

A16z-Backed Braveheart Biotech Seeks $318.8 Million in US IPO

A16z-backed Braveheart seeks $318.8 million in a US IPO, signaling continued vigor in the venture-backed biotech market.

Eli Lilly-backed Scribe Therapeutics files for $107.2 million IPO

Scribe Therapeutics, with Eli Lilly’s backing, files for a $107.2 million IPO, highlighting gene-editing sector momentum and potential biotech IPO revival.